Serum interleukin-23 associated with disease activitiy in psoriatic arthritis patient

Background: The pathogenesis of psoriatic arthritis has not yet been fully understood. Interleukin-23 (IL-23) dysregulation plays a dominant role in the development of chronic autoimmune inflammatory diseases including psoriatic arthritis. We aimed to examine the correlation between serum IL-23 and the parameters of psoriatic arthritis disease activity using DAPSA score. Methods: The cross sectional observational analytic study involved 32 research subjects of new psoriatic arthritis who were diagnosed based on CASPAR. Serum IL-23 levels were examined using the ELISA method with the Elabsience^R reagent. Disease activity using DAPSA scores was declared remission (score 0-4), mild (score >4-14), moderate (score >1-28), severe (score >28). Results: The subjects was 32 patients consisted 9 males and 23 females. The median age was 51 years, with range 17-60 years. The clinical presentation of symmetric polyartrhitis in 16 subjects (50%), asymmetric oligoarthritis in 13 subjects (13%), predominant DIP in 7 subjects (21.87%) and predominant spondyloarthritis (axial type) in 3 subjects (9.37%). The median DAPSA score was 21.6 (4.10-58.10). The median serum IL-23 level was 111.79 (27.54-3963) pg/mL. There was a significant positive correlation between serum IL-23 levels and DAPSA scores (p = 0.006, r = 0.472). Conclusion: Serum IL-23 levels associated with psoriatic arthritis disease activity using DAPSA score.